TBOPP, a DOCK1 Inhibitor, Potentiates Cisplatin Efficacy in Breast Cancer by Regulating Twist-mediated EMT.

ABSTRACT:

Background

DOCK1 has been reported to be involved in tumor progression and re-sistance.1-(2-(30-(trifluoromethyl)-[1,10-biphenyl]-4-yl)-2-oxoethyl)-5-pyrrolidinylsulfonyl2(1H)- pyridone (TBOPP) is a selective DOCK1 inhibitor; however, the role and molecular mechanisms of DOCK1 and its inhibition in breast cancer (BC) resistance remain poorly understood.

Objective

This study aims toinvestigate the underlying mechanisms of DOCK1 in BC resistance.

Objective

This study aims toinvestigate the underlying mechanisms of DOCK1 in BC resistance.

Methods

DOCK1 or Twist siRNA and Twist plasmid were used to explore the function of DOCK1 in vitro experiments. A mouse xenograft model was used for in vivo experiments.

Results

In the present study, we demon

SUBMITTER: Chen X 

PROVIDER: S-EPMC11826914 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature